Review Article

Effectiveness of Repeated Treatment with Botulinum Toxin Type A Across Different Conditions

Authors: Mark Forrest Gordon, MD, Rich Barron, MS


This review assessed the overall effectiveness of repeated treatments with botulinum toxin type A (BoNTA) across different conditions, as documented in the published literature. Forty-four original research articles reporting on 16 different conditions were identified that included data on the duration or efficacy of multiple treatments with BoNTA. All of the 44 studies found sustained or enhanced improvement in efficacy and/or duration over the follow-up period, which ranged from a few treatments to more than 10 years. Dosages did not change over time in 22 of the studies, increased in 4 studies, were not reported over time in 17 studies, and tended to increase then decrease in one study. Seven studies reported a statistically significant increase in the efficacy or duration of BoNTA over time. Results suggest that continued benefit with repeated BoNTA treatment is widely reported in the literature.

Key Points

* Forty-four original research articles reporting on 16 different conditions were identified that included data on the duration or efficacy of multiple treatments with botulinum toxin type A.

* All of the 44 studies found sustained or enhanced improvement in efficacy and/or duration over the follow-up period, which ranged from a few treatments to more than 10 years.

* Seven studies reported a statistically significant increase in the efficacy or duration of botulinum toxin type A over time.

* Results suggest that continued benefit with repeated botulinum toxin type A treatment is widely reported in the literature.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Verheyden J, Blitzer A, Brin MF. Other noncosmetic uses of BOTOX. Semin Cutan Med Surg2001;20:121–126.
2. Carruthers A, Carruthers J, Lowe NJ, et al. One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res 2004;7:1–20.
3. Relja M, Telarovic S. Botulinum toxin in tension-type headache. J Neurol 2004;251 (Suppl I):I12–I14.
4. Childers MK, Wilson DJ, Gnatz SM, et al. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil 2002;81:751–759.
5. Naumann M, Lowe NJ, Kumar CR, et al. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 2003;139:731–736.
6. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev1981;33:155–188.
7. MacKenzie I, Burnstock G, Dolly JO. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission.Neuroscience 1982;7:997–1006.
8. Ambache N. A further survey of the action of Clostridium botulinum toxin upon different types of autonomic nerve fibre. J Physiol 1951;113:1–17.
9. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245–258.
10. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004;44:35–42.
11. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management.Headache 2003;43(Suppl 1):S9-S15.
12. Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 1988;95:1529–1534.
13. Elston JS. The management of blepharospasm and hemifacial spasm. J Neurol 1992;239:5–8.
14. Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993;43:834–836.
15. Lagalla G, Danni M, Reiter F, et al. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil 2000;79:377–384.
16. Garcia Ruiz PJ, Pascual Pascual I, Sanchez Bernardos V. Progressive response to botulinum A toxin in cerebral palsy. Eur J Neurol 2000;7:191–193.
17. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 2003;43:853–860.
18. Jankovic J. Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. Adv Neurol 1988;50:583–591.
19. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry1990;53:633–639.
20. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998;108:1435–1441.
21. Arad-Cohen A, Blitzer A. Botulinum toxin treatment for symptomatic Frey's syndrome. Otolaryngol Head Neck Surg 2000;122:237–240.
22. Tsoy EA, Buckley EG, Dutton JJ. Treatment of blepharospasm with botulinum toxin. Am J Ophthalmol 1985;99:176–179.
23. Maurri S, Brogelli S, Alfieri G, et al. Beneficial effect of botulinum A toxin in blepharospasm: 16 months' experience with 16 cases. Ital J Neurol Sci 1988;9:337–344.
24. Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg 2001;108:208–214.
25. Boyd RN, Graham JEA, Nattrass GR, et al. Medium-term response characterization and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy. Eur J Neurol 1999;6(Suppl 4):S37-S45.
26. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2:237–254.
27. Bulstrode NW, Grobbelaar AO. Long-term prospective follow-up of botulinum toxin treatment for facial rhytides. Aesthetic Plast Surg 2002;26:356–359.
28. Vela MF, Richter JE, Wachsberger D, et al. Complexities of managing achalasia at a tertiary referral center: use of pneumatic dilatation, Heller myotomy, and botulinum toxin injection. Am J Gastroenterol2004;99:1029–1036.
29. Neubrand M, Scheurlen C, Schepke M, et al. Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy 2002;34:519–523.
30. Niamtu J III. Botulinum toxin A: a review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 2003;61:317–324.
31. Tsui JK, Fross RD, Calne S, et al. Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci 1987;14(3 Suppl):533–535.
32. Pullman SL, Greene P, Fahn S, et al. Approach to the treatment of limb disorders with botulinum toxin A: experience with 187 patients. Arch Neurol 1996;53:617–624.
33. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up.Neurology 1999;53:2102–2107.
34. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213–217.
35. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology1995;45:1743–1746.
36. Erdal J, Ostergaard L, Fuglsang-Frederiksen A, et al. Long-term botulinum toxin treatment of cervical dystonia: EMG changes in injected and noninjected muscles. Clin Neurophysiol1999;110:1650–1654.
37. Borodic GE, Ferrante R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 1992;12:121–127.
38. Physician's Desk Reference. BOTOX® (Botulinum Toxin Type A). Montvale, NJ, Thomson PDR, 2003, pp 552–554.
39. Calace P, Cortese G, Piscopo R, et al. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol 2003;13:331–336.
40. Shorr N, Seiff SR, Kopelman J. The use of botulinum toxin in blepharospasm. Am J Ophthalmol1985;99:542–546.
41. Dutton JJ, Buckley EG. Botulinum toxin in the management of blepharospasm. Arch Neurol1986;43:380–382.
42. Elston JS. Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections. Br J Ophthalmol 1987;71:664–668.
43. Ainsworth JR, Kraft SP. Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm. Ophthalmology 1995;102:2036–2040.
44. Snir M, Weinberger D, Bourla D, et al. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol2003;136:99–105.
45. Nussgens Z, Roggenkamper P. Long-term treatment of blepharospasm with botulinum toxin type A.Ger J Ophthalmol 1995;4:363–367.
46. Engstrom PF, Arnoult JB, Mazow ML, et al. Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophthalmology 1987;94:971–975.
47. Drummond GT, Hinz BJ. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time. Can J Ophthalmol 2001;36:398–403.
48. Ruusuvaara P, Setala K. Long-term treatment of involuntary facial spasms using botulinum toxin.Acta Ophthalmol (Copenh) 1990;68:331–338.
49. Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002;59:418–420.
50. Gonnering RS. Treatment of hemifacial spasm with botulinum A toxin: results and rationale. Ophthal Plast Reconstr Surg 1986;2:143–146.
51. Flanders M, Chin D, Boghen D. Botulinum toxin: preferred treatment for hemifacial spasm. Eur Neurol 1993;33:316–319.
52. Chen RS, Lu CS, Tsai CH. Botulinum toxin A injection in the treatment of hemifacial spasm. Acta Neurol Scand 1996;94:207–211.
53. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40:277–280.
54. Dubinsky RM, Gray CS, Vetere-Overfield B, et al. Electromyographic guidance of botulinum toxin treatment in cervical dystonia. Clin Neuropharmacol 1991;14:262–267.
55. Brashear A, Watts MW, Marchetti A, et al. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther 2000;22:1516–1524.
56. Hsiung GY, Das SK, Ranawaya R, et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17:1288–1293.
57. Damrose JF, Goldman SN, Groessl EJ, et al. The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia. J Voice 2004;18:415–422.
58. Ludlow CL, Bagley J, Yin SG, et al. A comparison of injection techniques using botulinum toxin injection for treatment of the spasmodic dysphonias. J Voice 1992;6:380–386.
59. Rubin AD, Wodchis WP, Spak C, et al. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II. Arch Otolaryngol Head Neck Surg 2004;130:415–420.
60. Hogikyan ND, Wodchis WP, Spak C, et al. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia. J Voice2001;15:576–586.
61. Aronson AE, McCaffrey TV, Litchy WJ, et al. Botulinum toxin injection for adductor spastic dysphonia: patient self-ratings of voice and phonatory effort after three successive injections.Laryngoscope 1993;103:683–692.
62. Mehta RP, Goldman SN, Orloff LA. Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes. Arch Otolaryngol Head Neck Surg 2001;127:393–399.
63. Balkrishnan R, Manuel JC, Smith BP, et al. Longitudinal examination of health outcomes associated with botulinum toxin use in children with cerebral palsy. J Surg Orthop Adv 2004;13:76–80.
64. Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics2001;108:1062–1071.
65. Rodriguez AA, McGinn M, Chappell R. Botulinum toxin injection of spastic finger flexors in hemiplegic patients. Am J Phys Med Rehabil 2000;79:44–47.
66. Gordon MF, Brashear A, Elovic E, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004;63:1971–1973.
67. Acquadro MA, Borodic GE. Treatment of myofascial pain with botulinum A toxin. Anesthesiology1994;80:705–706.
68. Wehrmann T, Kokabpick H, Jacobi V, et al. Long-term results of endoscopic injection of botulinum toxin in elderly achalasic patients with tortuous megaesophagus or epiphrenic diverticulum. Endoscopy1999;31:352–358.
69. D'Onofrio V, Annese V, Miletto P, et al. Long-term follow-up of achalasic patients treated with botulinum toxin. Dis Esophagus 2000;13:96–101.
70. Annese V, Basciani M, Borrelli O, et al. Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia. Muscle Nerve 1998;21:1540–1542.
71. Allescher HD, Storr M, Seige M, et al. Treatment of achalasia: botulinum toxin injection vs pneumatic balloon dilation: a prospective study with long-term follow-up. Endoscopy 2001;33:1007–1017.
72. Kolbasnik J, Waterfall WE, Fachnie B, et al. Long-term efficacy of Botulinum toxin in classical achalasia: a prospective study. Am J Gastroenterol 1999;94:3434–3439.
73. Storr M, Allescher HD, Rosch T, et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up. Gastrointest Endosc 2001;54:754–759.
74. Lewin JS, Bishop-Leone JK, Forman AD, et al. Further experience with Botox injection for tracheoesophageal speech failure. Head Neck 2001;23:456–460.
75. Lowe PL, Cerdan-Sanz S, Lowe NJ. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Dermatol Surg 2003;29:545–548.
76. Giannantoni A, Mearini E, Di Stasi SM, et al. New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 2004;56:79–87.
77. Mauriello Jr, JA Dhillon S, Leone T, et al. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. Br J Ophthalmol 1996;80:1073–1076.
78. Mauriello JA Jr., Leone T, Dhillon S, et al. Treatment choices of 119 patients with hemifacial spasm over 11 years. Clin Neurol Neurosurg 1996;98:213–216.
79. Mauriello JA, Aljian J. Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years. Br J Ophthalmol 1991;75:737–739.
80. Brashear A, Bergan K, Wojcieszek J, et al. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000;15:150–153.
81. Karp BI, Cole RA, Cohen LG, et al. Long-term botulinum toxin treatment of focal hand dystonia.Neurology 1994;44:70–76.
82. Damron TA, Greenwald TA, Breed AL. Chronologic outcome of surgical tendoachilles lengthening and natural history of gastroc-soleus contracture in cerebral palsy: a two-part study. Clin Orthop Relat Res 1994;301:249–255.
83. Ludlow CL, Hallett M, Sedory SE, et al. The pathophysiology of spasmodic dysphonia and its modification by botulinum toxin. In: Berardelli A, Benecke R, Manfredi M, Marsden CM (eds). Motor Disturbances II. New York, Academic Press, 1990, pp 273–288.
84. Brin MF, Blitzer A, Stewart C, et al. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin: review and technical aspects. In: Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris KS (eds). Neurological Disorders of the Larynx. New York, Thieme, 1992, pp 214–228.
85. Zwirner P, Murry T, Swenson M, et al. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope1992;102:400–406.
86. Giladi N, Meer J, Kidan H, et al. Long-term remission of idiopathic cervical dystonia after treatment with botulinum toxin. Eur Neurol 2000;44:144–146.
87. Filippi GM, Errico P, Santarelli R, et al. Botulinum-A toxin effects on rat jaw muscle spindles. Acta Oto-Laryngol 1993;113:400–404.
88. Dressler D, Munchau A, Bhatia KP, et al. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 2002;47:118–121.
89. Comella CL, Jankovic J, Daggett S, et al. Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia.Neurology 2004;62(7 Suppl 5):A511.
90. Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996;46:1066–1072.
91. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395–400.
92. Gelber DA, Good DC, Dromerick A, et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke2001;32:1841–1846.
93. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis.Curr Med Res Opin 2004;20:981–990.